AVNS Stock Forecast 2025-2026
Distance to AVNS Price Targets
AVNS Price Momentum
🤔 Considering Avanos (AVNS)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Latest AVNS Stock Price Targets & Analyst Predictions
Based on our analysis of 9 Wall Street analysts, AVNS has a neutral consensus with a median price target of $17.00 (ranging from $17.00 to $17.00). The overall analyst rating is Buy (6.0/10). Currently trading at $14.46, the median forecast implies a 17.6% upside. This outlook is supported by 0 Buy, 2 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AVNS Analyst Ratings
AVNS Price Target Range
Latest AVNS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AVNS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 7, 2024 | JMP Securities | Daniel Stauder | Market Perform | Reiterates | $0.00 |
| Jul 25, 2023 | Keybanc | Matthew Mishan | Sector Weight | Downgrade | $0.00 |
| Jun 21, 2023 | Stifel | Rick Wise | Hold | Reiterates | $25.00 |
| May 22, 2023 | CL King | Kristen Stewart | Buy | Initiates | $31.00 |
| May 4, 2023 | Morgan Stanley | Drew Ranieri | Underweight | Maintains | $26.00 |
| Feb 22, 2023 | Morgan Stanley | Drew Ranieri | Underweight | Maintains | $28.00 |
| Jan 6, 2023 | Morgan Stanley | Drew Ranieri | Underweight | Maintains | $26.00 |
| Nov 3, 2022 | Keybanc | Matthew Mishan | Overweight | Maintains | $34.00 |
| Oct 11, 2022 | Morgan Stanley | Drew Ranieri | Underweight | Maintains | $24.00 |
| Aug 10, 2022 | Keybanc | Matthew Mishan | Overweight | Maintains | $38.00 |
| Jul 18, 2022 | Stifel | Rick Wise | Hold | Maintains | $28.00 |
| Jul 15, 2022 | Morgan Stanley | Drew Ranieri | Underweight | Maintains | $28.00 |
| May 5, 2022 | Morgan Stanley | Underweight | Maintains | $33.00 | |
| Feb 24, 2022 | Keybanc | Matthew Mishan | Overweight | Maintains | $41.00 |
| Jan 7, 2022 | Morgan Stanley | Underweight | Maintains | $36.00 | |
| Aug 4, 2021 | Morgan Stanley | Drew Ranieri | Underweight | Maintains | $41.00 |
| Aug 4, 2021 | Keybanc | Matthew Mishan | Overweight | Maintains | $47.00 |
| Aug 4, 2021 | Stephens & Co. | Chris Cooley | Equal-Weight | Downgrade | $45.00 |
| Jan 8, 2021 | KeyBanc | Overweight | Maintains | $0.00 | |
| Jan 8, 2021 | Keybanc | Paul Knight | Overweight | Maintains | $55.00 |
Avanos Medical Inc. (AVNS) Competitors
The following stocks are similar to Avanos based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Avanos Medical Inc. (AVNS) Financial Data
Avanos Medical Inc. has a market capitalization of $664.52M with a P/E ratio of 34.4x. The company generates $687.80M in trailing twelve-month revenue with a -57.0% profit margin.
Revenue growth is +3.6% quarter-over-quarter, while maintaining an operating margin of +4.9% and return on equity of -37.4%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Avanos Medical Inc. (AVNS) Business Model
About Avanos Medical Inc.
Develops medical devices for improved patient care.
Avanos Medical generates revenue by designing and manufacturing medical devices that cater to chronic care and pain management. The company sells its products to healthcare providers, including hospitals and outpatient facilities, focusing on enhancing patient outcomes while managing procedural costs.
Avanos Medical emphasizes innovation in healthcare solutions, aiming to meet the evolving demands of healthcare providers globally. Its product range includes enteral feeding systems and respiratory therapy equipment, which are essential in various medical settings.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
2,227
CEO
Mr. Michael C. Greiner CPA
Country
United States
IPO Year
2018
Website
avanos.comAvanos Medical Inc. (AVNS) Latest News & Analysis
New Strong Sell Stocks for March 3rd
12 days agoAVNS, CSX, and STZ have been assigned a Zacks Rank #5 (Strong Sell) as of March 3, 2025.
AVNS, CSX, and STZ receiving a Zacks Rank #5 indicates a bearish outlook, suggesting potential declines in their stock prices, prompting caution among investors.
Avanos reported strong performance in its Digestive Health segment for Q4 2024, overcoming global macroeconomic challenges.
Avanos' strong performance in Digestive Health indicates resilience and potential for growth, suggesting stability and opportunities for profitability amid broader economic challenges.
Avanos Medical, Inc. (NYSE: AVNS) announced its fourth quarter and full-year results for 2024 on February 26, 2025.
Avanos Medical's quarterly and annual results can impact stock performance, investor sentiment, and future growth projections, influencing investment decisions and market positioning.
Avanos Medical (AVNS) reported Q3 earnings of $0.43 per share, exceeding the Zacks Consensus Estimate of $0.40, and up from $0.36 per share the previous year.
Avanos Medical's earnings beat expectations and show year-over-year growth, indicating strong performance and potential for future profitability, which can positively influence stock value.
Avanos Medical, Inc. (NYSE: AVNS) will hold a conference call on February 26, 2025, at 9 a.m. to discuss its Q4 and full year 2024 financial results and business highlights.
Avanos Medical's upcoming conference call will reveal financial performance and strategic insights, influencing stock valuation and investor sentiment.
Frequently Asked Questions About AVNS Stock
What is Avanos Medical Inc.'s (AVNS) stock forecast for 2025?
Based on our analysis of 9 Wall Street analysts, Avanos Medical Inc. (AVNS) has a median price target of $17.00. The highest price target is $17.00 and the lowest is $17.00.
Is AVNS stock a good investment in 2025?
According to current analyst ratings, AVNS has 0 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $14.46. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for AVNS stock?
Wall Street analysts predict AVNS stock could reach $17.00 in the next 12 months. This represents a 17.6% increase from the current price of $14.46. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Avanos Medical Inc.'s business model?
Avanos Medical generates revenue by designing and manufacturing medical devices that cater to chronic care and pain management. The company sells its products to healthcare providers, including hospitals and outpatient facilities, focusing on enhancing patient outcomes while managing procedural costs.
What is the highest forecasted price for AVNS Avanos Medical Inc.?
The highest price target for AVNS is $17.00 from at , which represents a 17.6% increase from the current price of $14.46.
What is the lowest forecasted price for AVNS Avanos Medical Inc.?
The lowest price target for AVNS is $17.00 from at , which represents a 17.6% increase from the current price of $14.46.
What is the overall AVNS consensus from analysts for Avanos Medical Inc.?
The overall analyst consensus for AVNS is neutral. Out of 9 Wall Street analysts, 0 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $17.00.
How accurate are AVNS stock price projections?
Stock price projections, including those for Avanos Medical Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
